Background: Multiple sclerosis (MS) displays a month-of-birth effect, with an excess of individuals
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The major histocompatibility complex (MHC) class II region is the key susceptibility locus in MS, and other susceptibility genes identified to date have a much smaller effect on risk. 2 The principal MHC class II haplotype that increases MS risk in individuals of Northern European descent is HLA-DQB1*0602-DQA1*0102 -DRB1*1501-DRB5*0101, 3 although other HLA-DRB1 haplotypes have important influences on disease risk. [4] [5] [6] [7] [8] [9] The frequency of HLA-DRB1*15 in much of Europe mirrors the prevalence of the disease, 10, 11 with exceptions in the Mediterranean, where MS is associated with other HLA-DRB1 alleles.
The fact that most monozygotic twins are discordant for MS is widely believed to indicate the importance of the environment in disease pathogenesis. 12 The investigation of birth patterns is a classic approach in epidemiology to look for environmental effects. 13 The finding of a birth pattern suggests that the origins of a disease date to very early in life and hints at risk factors that vary seasonally. 13 In MS, a pooled analysis of more than 40,000 patients from Canada, Great Britain, Denmark, and Sweden showed that approximately 10% fewer people with MS were born in November, with a similarly sized increase in May. 14 Furthermore, it was shown that this month-of-birth effect influences the MS clinical phenotype by being present almost exclusively in individuals with relapsing-remitting MS. 15 The month-of-birth effect was shown to be more prominent in familial MS cases. 14 This could indicate that the month-of-birth risk factor interacts with disease predisposing genes. Therefore, in this study we examined the hypothesis of a month-of-birth interaction with MS associated MHC class II genes.
METHODS Patient ascertainment. Canadian patients
with MS (n ϭ 2,248) were ascertained through the ongoing Canadian Collaborative Project on the Genetic Susceptibility to Multiple Sclerosis (CCPGSMS), for which the methodology has been previously described. 16 Swedish patients with MS (n ϭ 1,982) were recruited from the Department of Neurology, Karolinska University Hospital, Stockholm, and from several neurology clinics all over Sweden. Norwegian patients (n ϭ 604) were recruited from the Oslo MS registry at the Department of Neurology, Oslo University Hospital, Ullevål, Oslo, Norway.
Control ascertainment. Unaffected siblings of Canadian patients with MS (n ϭ 659) were ascertained through the CCPGSMS.
Swedish unaffected MS controls (n ϭ 655) were recruited from the national population register and matched to patients with MS on the basis of residence, sex, and date of birth. Nine hundred twenty-five controls were included from a nationwide study of risk factors for diabetes in Sweden. 17 Swedish unaffected diabetes controls were recruited from the national population register and matched to patients with diabetes on the basis of residence, sex, and date of birth. Swedish individuals with no autoimmune diseases (n ϭ 1,474) were randomly selected from Central Sweden based on date of birth, sex, and residence to match patients with rheumatoid arthritis from the Epidemiologic Investigation of Rheumatoid Arthritis (EIRA) study. 18 Gender-matched Norwegian healthy controls (n ϭ 1,002) were recruited from the Norwegian Bone Marrow Donor Registry (NBMDR). The human leukocyte antigen profile of the 1,002 controls used were similar to the profile of the entire NBMDR (more than 20,000 Norwegian controls).
Standard protocol approvals, registrations, and patient consents. Each participating clinic in the CCPGSMS obtained ethical approval from the relevant institutional review board, and the entire project was reviewed and approved by the University of British Columbia and the University of Western Ontario. Informed consent was obtained from all patients. The ethical board of Karolinska Institutet, Stockholm, Sweden, approved of the study, and informed consent was obtained from all Swedish patients with MS and MS controls.
The study of Norwegian patients with MS and controls was approved by the Regional Committee for Medical Research Ethics of South and Eastern Norway, and informed consent was obtained from all participating individuals.
Genotyping. HLA-DRB1 typing was performed either using restriction fragment length polymorphisms 19 or with sequence specific amplification.
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Statistical analysis. Tests of association between month of birth and the frequency of HLA-DRB1*15 were assessed by comparing the allele frequency in each month against the allele frequency in all other months by using a 2 ϫ 2 2 test of independence.
RESULTS There were no significant differences in frequency of births each month when comparing patients and controls (data not shown). DISCUSSION Although the role of the environment is clearly important in determining MS risk, the relevant underlying mechanisms have remained elusive, and there has been no experimental support for a direct environment-gene interaction. The data in this study support the notion that the risk factor for the timing of birth effect interacts with the region exerting the single strongest genetic effect in MS, that which contains HLA-DRB1.
The pooled Canadian, Swedish, and Norwegian MS cohort represents the largest number of patients genotyped for this locus to date. Nevertheless, the pooled genotyped cohort is smaller than the epidemiologic cohort used to uncover a month-of-birth effect in MS 14 and is thus perhaps underpowered to detect relevant effects.
The nature of the timing of birth effect is as yet unknown, but maternal vitamin D deficiency is a plausible candidate. 14, 21, 22 At present, we cannot be sure when the key risk period is (winter pregnancy or spring birth?), and thus other environmental factors (for example infection) all need to be considered. We have recently shown that vitamin D influences the expression of HLA-DRB1*15-bearing haplotypes in particular. 22 Variation in the deviation pattern of MS births by latitude would support a vitamin D hypothesis. Indeed, this was observed in Sicily, 23 but conflictingly, the month of birth effect in Sardinia was similar to that of Northern Europeans. 24 This would suggest that prenatal or perinatal environmental MS risk factors are commonly distributed among different populations. However, twin concordance in MS has been shown to be influenced by latitude, 25 and furthermore, Sardinia is exceptional with regards to its MS prevalence. Thus, more detailed study of month-of-birth patterns in other regions are required. Further work is needed to confirm the results obtained and to fully elucidate the mechanism of this gene-environment interaction, which may be key to disease prevention.
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